Rapid Micro Biosystems (NASDAQ:RPID) Stock Dropped to “Hold” by Lake Street Capital

Lake Street Capital lowered shares of Rapid Micro Biosystems (NASDAQ:RPID – Free Report) from a buy rating to a hold rating in a report issued on Monday morning,FinViz reports. The firm currently has $0.75 price target on the stock.

Several other brokerages also recently issued reports on RPID. JPMorgan Chase & Co. set a $0.75 price objective on shares of Rapid Micro Biosystems in a research report on Tuesday. Roth Capital cut shares of Rapid Micro Biosystems from a “buy” rating to a “neutral” rating and cut their price objective for the company from $3.00 to $0.75 in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, October 15th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $1.81.

Check Out Our Latest Analysis on Rapid Micro Biosystems

Rapid Micro Biosystems Trading Up 13.7%

NASDAQ:RPID opened at $0.74 on Monday. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.55 and a quick ratio of 1.51. The business’s 50-day simple moving average is $0.91 and its 200-day simple moving average is $2.06. Rapid Micro Biosystems has a fifty-two week low of $0.58 and a fifty-two week high of $4.94. The stock has a market capitalization of $37.12 million, a PE ratio of -0.66 and a beta of 1.52.

Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.01). Rapid Micro Biosystems had a negative return on equity of 177.04% and a negative net margin of 145.56%. The company had revenue of $9.53 million for the quarter, compared to analyst estimates of $9.85 million. Sell-side analysts expect that Rapid Micro Biosystems will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Rapid Micro Biosystems

A number of hedge funds and other institutional investors have recently made changes to their positions in RPID. Renaissance Technologies LLC boosted its holdings in Rapid Micro Biosystems by 9.5% during the first quarter. Renaissance Technologies LLC now owns 126,617 shares of the company’s stock worth $287,000 after purchasing an additional 10,990 shares during the last quarter. Bank of America Corp DE increased its stake in Rapid Micro Biosystems by 139.9% in the 1st quarter. Bank of America Corp DE now owns 31,014 shares of the company’s stock valued at $70,000 after buying an additional 18,085 shares during the last quarter. Temasek Holdings Private Ltd acquired a new stake in Rapid Micro Biosystems in the 1st quarter valued at $50,000. Dimensional Fund Advisors LP increased its stake in Rapid Micro Biosystems by 55.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 87,589 shares of the company’s stock valued at $199,000 after buying an additional 31,407 shares during the last quarter. Finally, Pekin Hardy Strauss Inc. bought a new stake in Rapid Micro Biosystems during the 3rd quarter worth about $41,000. 52.60% of the stock is currently owned by institutional investors and hedge funds.

Top Rapid Micro Biosystems Stories

Investors following RPID have been watching these stories:

  • Positive Sentiment: Merck KGaA signed a definitive agreement to acquire all outstanding RPID shares for $0.75 each in cash. Merck said Rapid Micro’s Growth Direct platform would strengthen its pharmaceutical quality-control workflow offerings. Acquisition announcement
  • Neutral Sentiment: Law firms announced investigations into whether the $0.75 offer fairly values RPID and whether deal terms could limit competing offers. These are inquiries, not findings, but could add uncertainty around the transaction. Shareholder investigation report
  • Negative Sentiment: Third-quarter results were slightly below analyst expectations: RPID reported a $0.22-per-share loss versus estimates of $0.21, and revenue of $9.53 million versus estimates of $9.85 million. The company also filed a notification of late quarterly filing, adding a reporting concern. Third-quarter results Late filing report

About Rapid Micro Biosystems

(Get Free Report)

Rapid Micro Biosystems develops automated microbial detection systems for pharmaceutical, biotechnology and other life sciences manufacturers. Its products are designed to support quality-control testing by identifying and measuring microbial growth in manufacturing environments and products. The company’s Growth Direct platform combines laboratory instruments, consumables and software to automate microbial testing. Its applications include sterility testing, bioburden testing and environmental monitoring, helping manufacturers assess contamination during production.

See Also

Receive News & Ratings for Rapid Micro Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapid Micro Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.